| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection
|
Tsou H.-H.; Yang H.-C.; Hsiao C.-F.; Hsiung C.A.; Liu T.-W.; Chuang M.-H.; Wu H.-Y.; Hsu Y.-T.; Tsui C.-W.; Chen P.-J.; ANN-LII CHENG; Hsu C.; Taiwan Cooperative Oncology Group |
| 臺大學術典藏 |
2021-08-31T06:29:19Z |
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
|
ANN-LII CHENG; Hsu C.; Chan S.L.; Choo S.-P.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-08-31T06:29:15Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-08-24T02:10:06Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang F.-C.; Chen T.W.-W.; TAO-MIN HUANG; Lin W.-C.; Liu J.-S.; Chiang W.-C.; Chen Y.-M.; Hsu C.; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2021-08-23T03:43:53Z |
Spectrum of cancer patients receiving renal biopsy
|
FAN-CHI CHANG; Chen T.W.-W.; Huang T.T.-M.; Lin W.-C.; Liu J.-S.; Chiang W.-C.; Chen Y.-M.; Hsu C.; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2021-08-18T07:39:08Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
Yang S.-H.; Kuo T.-C.; Wu H.; JHE-CYUAN GUO; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-18T07:39:05Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Lu L.-C.; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; JHE-CYUAN GUO; Liu T.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-18T07:39:04Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
Yang S.-H.; JHE-CYUAN GUO; Hsu C.; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-16T03:26:41Z |
Predictors of bloodstream infection associated with permanently implantable venous port in solid cancer patients
|
I-CHUN CHEN; Hsu C.; Chen Y.C.; Chien S.F.; Kao H.F.; Chang S.Y.; Hu F.C.; Yeh K.H. |
| 臺大學術典藏 |
2021-08-16T03:26:41Z |
Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era
|
I-CHUN CHEN; Lin C.H.; Huang C.S.; Lien H.C.; Hsu C.; Kuo W.H.; Lu Y.S.; Cheng A.L. |
| 臺大學術典藏 |
2021-08-16T03:26:40Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.; I-CHUN CHEN; Hsu C.; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-12T04:01:31Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
YANG SHIH-HUNG; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-12T04:01:30Z |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Kuo Y.-H.; Lin C.-H.; Shau W.-Y.; Chen T.-J.; YANG SHIH-HUNG; Huang S.-M.; Hsu C.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-12T04:01:27Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
YANG SHIH-HUNG; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-12T04:01:24Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
YANG SHIH-HUNG; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-12T04:01:23Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; YANG SHIH-HUNG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-12T04:01:22Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.; Chen M.-H.; YANG SHIH-HUNG; Hsu C.; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-11T03:46:53Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
ZHONG-ZHE LIN; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-08-11T03:46:52Z |
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
|
ZHONG-ZHE LIN; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:52Z |
Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival
|
Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; ZHONG-ZHE LIN; Chang M.-C.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:50Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Shen Y.-C.; ZHONG-ZHE LIN; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:49Z |
Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
|
Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:49Z |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
|
Hsu C.-H.; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; ZHONG-ZHE LIN; Chao T.-Y.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:48Z |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy
|
Shao Y.-Y.; ZHONG-ZHE LIN; Chen T.-J.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:47Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:46Z |
Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma
|
Shau W.-Y.; Shao Y.-Y.; Yeh Y.-C.; ZHONG-ZHE LIN; Kuo R.; Hsu C.-H.; Hsu C.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-11T03:46:46Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
ZHONG-ZHE LIN; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:45Z |
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems
|
Shao Y.-Y.; Lu L.-C.; ZHONG-ZHE LIN; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:43Z |
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
|
Shao Y.-Y.; Liang P.-C.; Wu Y.-M.; Huang C.-C.; Huang K.-W.; Cheng J.C.; Hsu C.-H.; Hsu C.; Cheng A.-L.; ZHONG-ZHE LIN |
| 臺大學術典藏 |
2021-08-11T03:46:43Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
ZHONG-ZHE LIN; Shau W.-Y.; Hsu C.; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-11T03:46:42Z |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma
|
Ou D.-L.; Chang C.-J.; Jeng Y.-M.; Lin Y.-J.; ZHONG-ZHE LIN; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:42Z |
Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer
|
Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; ZHONG-ZHE LIN; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:41Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.; ZHONG-ZHE LIN; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2021-08-11T03:46:38Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2021-08-11T03:46:37Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:36Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; ZHONG-ZHE LIN; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-11T03:46:36Z |
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
|
ZHONG-ZHE LIN; Hsu C.; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-11T03:46:34Z |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
|
ZHONG-ZHE LIN; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C. |
| 臺大學術典藏 |
2021-08-11T03:46:33Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; ZHONG-ZHE LIN; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2021-08-10T03:53:07Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
SHIH-HUNG YANG; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-10T03:53:06Z |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Kuo Y.-H.; Lin C.-H.; Shau W.-Y.; Chen T.-J.; SHIH-HUNG YANG; Huang S.-M.; Hsu C.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-10T03:53:04Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
SHIH-HUNG YANG; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2021-08-10T03:53:01Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-10T03:53:01Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
SHIH-HUNG YANG; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2021-08-10T03:53:00Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG; Hsu C.; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2021-08-05T02:37:30Z |
Study on the transient response to the point-to-point motion controls on a dual-axes air-bearing planar stage
|
Kuo F.-C;Hsu C;Hsieh M.-R;Yen J.-Y;Chen L.-C;Chung T.-T;Wang F.-C.; Kuo F.-C; Hsu C; Hsieh M.-R; Yen J.-Y; Chen L.-C; Chung T.-T; Wang F.-C.; LIANG-CHIA CHEN |
| 臺大學術典藏 |
2021-08-03T07:10:54Z |
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
|
Hung Y.-P.; YU-YUN SHAO; Lee J.-M.; Hsu C.; Hsu C.-H.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2021-08-03T07:10:53Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
YU-YUN SHAO; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2021-08-03T07:10:52Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.; YU-YUN SHAO; Hsu C.; Hsu C.-H.; Lee J.-M.; Yang M.-H.; Chao Y. |
